Assessment of hemodialysis patients’ response to Erythropoietin
Abstract
Introduction: Anemia is a common complication in hemodialysis patients and its presence is associated with a reduced quality of life, increases mortality rates, and its treatment constitutes an economic burden.
Research Methods: A prospective study was conducted that included 112 hemodialysis patients at Tishreen University Hospital in Lattakia, during the period from October 2021 to March 2022. Erythropoietin was administered to each patient with a hemoglobin value ≤11.5 g/dl in initial doses. 20-50 units/kg*3 weekly, then the dose was later adjusted according to the hemoglobin values that were monitored monthly, but not to exceed 300 units/kg weekly. The type of erythropoietin used was subcutaneous alpha and beta.
Results: The number of patients who responded to the treatment was 35 patients. By comparing the characteristics of the responding patients with the non-responders, we noticed that there was no significant difference in the demographic characteristics or the cause of renal insufficiency, and that URR% was statistically significant by 5% higher within the responders group, and for the values of both Ferritin, calcium and PTH were statistically significant after 6 months, and there was a close relationship between high ERI values, high PLR values, and non-response to treatment. A significant decrease in dependence on blood transfusion occurred. All patients with severe anemia. We reached the maximum dose of erythropoietin in 84 patients out of 112, of whom only 17 patients achieved a response at the end of the study from those treated with the maximum dose, while 8 patients reached the target hemoglobin without reaching the target. for the maximum dose of erythropoietin. Conclusions: Ferritin, PTH, Ca and the adequacy of dialysis played a role in the response to erythropoietin, and there was a significance of the ERI and the ratio of platelets to lymphocytes in predicting non-response, while increasing the dose of erythropoietin did not increase the chances of improving hemoglobin values in our study.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.